Pharmaceutical Corporate Social Responsibility Report Information Disclosure

Corporate Social Responsibility is practical experienced and theoretical rich and matured in some developed countries, such as the United States, Germany, Britain, France and other countries. With the rapid of social-economic development, China’s enterprises are increasingly conscious of their social, political and other stakeholders, Corporate Social Responsibility commitment has become an inevitable choice for the growth and development. However, the development of our social responsibility are late, our social responsibility is still more reflected in the theoretical aspects, in recent years, the media exposure of "Hayao pollution" and the2012poison capsules events, these events make public begin to focus on the pharmaceutical corporate social responsibility performance, especially the importance of corporate social responsibility report. Four Pharmaceutical Group are a leading position in the pharmaceutical industry, according to Chinese corporate social responsibility report rating report released by the White Paper, their social responsibility are also in the forefront of the industry, their reports are typical.This paper use literature research and summarize the major research results on corporate social responsibility information disclosure. The study found that Our study is relatively backward, the majority remain in theoretical stage, Although there are some empirical studies carried out, but。they almost all learned from foreign research methods, and not combined with China’s national conditions, while case studies and industry is relatively small industry. This paper mainly use standardized methods and case studies, analyze the social responsibility report on China’s four major listed pharmaceutical Group and its affiliated companies, expanded on "ask questions-Analysis-Experience-Policy Recommendations" ideas.First, overview pharmaceutical company’s social responsibility and status of their reports,then analyze four major pharmaceutical industry status of corporate social responsibility report, found that report information disclosure problems in CSR. The problems mainly reflected in the content of the report incomplete, negative information less arbitrary framework, vague describing, insufficient third-party certification, low stakeholder participation. In response to these issues of discovery, the reasons for these problems are:poor corporate voluntary disclosure, not perfect standards and so on. In comparison, foreign pharmaceutical CSR framework is complete,such as AstraZeneca corporate social responsibility report, we could find specific metrics in foreign CSR, they are also easier to understand and measure.;G3application is strong in their reports. Meanwhile, companies focus on communication with stakeholders, the reader can get report and feedback through the official website, email and others. Finally, the article learn from foreign pharmaceutical industry experience in corporate social responsibility report, proposing formulating pharmaceutical CSR reporting framework and building social responsibility performance indicators, strengthening public opinion, third-party certification, and improving stakeholder communication and other recommendations. Thus promoting China’s pharmaceutical enterprises to fulfill their social responsibility category, and strengthening their social responsibility report information disclosure, and promoting the process of internationalization of China’s pharmaceutical enterprises, and enrich our corporate social responsibility reports related theories.